Substituted quinoxaline compounds for the inhibition of PASK
申请人:McCall John M.
公开号:US08916561B2
公开(公告)日:2014-12-23
Disclosed herein are substituted quinoxaline of Formula (I):
and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
This document provides compounds that are inhibitors of NF-κB activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, or autoimmune diseases.
[EN] METHODS AND MATERIALS FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY<br/>[FR] PROCÉDÉS ET MATÉRIAUX POUR INHIBER L'ACTIVITÉ NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE
申请人:[en]UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
公开号:WO2022109285A1
公开(公告)日:2022-05-27
This document provides compounds that are inhibitors of NAMPT activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, autoimmune conditions, and conditions characterized by acute or sub-acute neuronal injury.
HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
申请人:McCall John M.
公开号:US20120225863A1
公开(公告)日:2012-09-06
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.